Advantage Alpha Capital Partners LP Krystal Biotech, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $337 Million
- Q2 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 2,894 shares of KRYS stock, worth $525,810. This represents 0.12% of its overall portfolio holdings.
Number of Shares
2,894
Previous 3,569
18.91%
Holding current value
$525,810
Previous $643,000
38.26%
% of portfolio
0.12%
Previous 0.18%
Shares
3 transactions
Others Institutions Holding KRYS
# of Institutions
311Shares Held
24.7MCall Options Held
417KPut Options Held
485K-
Black Rock Inc. New York, NY3.95MShares$717 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.82MShares$513 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.66MShares$483 Million6.67% of portfolio
-
State Street Corp Boston, MA1.36MShares$246 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA942KShares$171 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.66B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...